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Abstract
Mutations in the Janus kinase 2 (JAK2) gene have become an important identifier for the Philadelphia-chromosome negative
chronic myeloproliferative neoplasms. In contrast to the JAK2V617F mutation, the large number of JAK2 exon 12 mutations
has challenged the development of quantitative assays. We present a highly sensitive real-time quantitative PCR assay for
determination of the mutant allele burden of JAK2 exon 12 mutations. In combination with high resolution melting analysis
and sequencing the assay identified six patients carrying previously described JAK2 exon 12 mutations and one novel
mutation. Two patients were homozygous with a high mutant allele burden, whereas one of the heterozygous patients had
a very low mutant allele burden. The allele burden in the peripheral blood resembled that of the bone marrow, except for
the patient with low allele burden. Myeloid and lymphoid cell populations were isolated by cell sorting and quantitative PCR
revealed similar mutant allele burdens in CD16+ granulocytes and peripheral blood. The mutations were also detected in B-
lymphocytes in half of the patients at a low allele burden. In conclusion, our highly sensitive assay provides an important
tool for quantitative monitoring of the mutant allele burden and accordingly also for determining the impact of treatment
with interferon-a-2, shown to induce molecular remission in JAK2V617F-positive patients, which may be a future treatment
option for JAK2 exon 12-positive patients as well.
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Introduction
Somatic mutations in the Janus kinase 2 (JAK2) gene contribute
significantly to the pathogenesis of Philadelphia chromosome –
negative chronic myeloproliferative neoplasms (MPN). In particu-
lar, polycythemia vera (PV) is in most cases associated with the
JAK2V617F mutation. As a consequence, constitutive phosphory-
lation of JAK2 results in activation of downstream signalling
pathways, leading to cytokine-independent growth of haematopoi-
etic progenitors and increased production of cells of the myeloid
lineage [1]. The identification of JAK2 as a therapeutic target in the
treatment of MPNs has been a major contribution towards the
understanding and clinical management of these diseases [2–6].
Several studies have shown that small molecule JAK2-inhibitors
affect growth and viability of the neoplastic cells but also possess
potent anti-inflammatory effects and display remarkable resolution
of hypermetabolic symptoms in concert with reduction of
splenomegaly in patients with myelofibrosis (MF) [7–13]. Although
significant reduction of the mutant allele burden has been reported
in a subgroup of patients [13] the JAK2-inhibitors in general do not
influencetheJAK2V617Falleleburden[14,15].Thepresenceofthe
JAK2V617F mutation has been established as a risk factor for
thrombosis [16], but the relationship between mutant allele burden
and the risk of thrombosis remains controversial [17–19]. However,
the observations that the JAK2V617F mutation per se induces
increasing genetic instability [20], in addition to the association
between the JAK2V617F mutant allele burden and both disease
phenotype and MF-free survival, support the contention of early
intervention with agents having the potential to reduce the
malignant clone [18]. In this context, interferon (IFN)-a-2 (2a and
2b), has been shown to induce major - and in a subset of patients
also - complete molecular remissions in JAK2V617F-positive
patients with essential thrombocytosis (ET) and PV [21]. Patients
with JAK2 exon 12 positive PV appear to progress along a clinical
course similar to JAK2V617F -positive PV with regard to risk
factors, including the development of thrombosis and post-PV MF
[22]. This observation suggests IFN-a-2 to be a rational therapeutic
approach aiming at inducing minimal residual disease with low-
burden JAK2 exon 12 as well. Monitoring the impact of treatment
upontheneoplasticclonerequiresa robustmethod todeterminethe
mutant allele burden with high sensitivity in order to be able to
assess deep molecular remissions. For the purpose of monitoring the
mutant allele burden of the JAK2V617F mutation sensitive,
quantitative PCR (qPCR) assays have been developed [23,24]. As
opposed to the single nucleotide substitution of JAK2V617F, at least
37 different JAK2 exon 12 mutations have been described, residing
in a region involving amino acids V536-F547 [25]. For identifica-
tion of JAK2 exon 12 mutations, high resolution melting (HRM)
analysis techniques have emerged as superior to both common
allele-specific PCR assays and Sanger sequencing in sensitivity and
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assays have demonstrated high sensitivity for selected JAK2 exon 12
mutations [26,29], but the large amount and variability of
mutations have complicated the development of quantitative assays
necessary for the evaluation of remission -inducing agents. In the
present study we have developed a highly sensitive quantitative real-
time qPCR technique for the most frequently occurring JAK2 exon
12 mutations and used this assay to investigate the proportion of
mutated cells in different peripheral blood (PB) cell lineages of JAK2
exon 12 positive patients. In addition, a novel JAK2 exon 12
mutation is reported.
Results
Identification of the JAK2 exon 12 mutations
In cohort 1, four patients (6.7%, n=60) were found JAK2 exon
12 positive (PV1-PV4) (Table S1). Two patients were identified
with the N542-E543del mutation by qPCR screening, one patient
with a V536-I546dup11 mutation and one patient with a novel
mutation involving a 10 base-pair deletion and a four base-pair
insertion; F537-I540delinsLV were identified by Sanger sequenc-
ing (Figure 1A). In cohort 2, HRM analysis identified two patients
with JAK2 exon 12 mutations (1.96%, n=102): one patient with a
N542-E543del (PV5) and one patient with a K539L mutation
(PV6) (Figure 1B). The mutations identified by qPCR and Sanger
sequencing were validated by HRM analysis and the mutations
identified in patients of cohort 2 were validated by qPCR and
Sanger sequencing. Neither Sanger sequencing nor HRM could
confirm the N542-E543del mutation of PV2 identified by qPCR
(Figure 1B). Consistent with these observations Epo-independent
Erythroid Colony (EEC) -growth was detected in cultures of
mononuclear cells from all patients except PV2 (Figure 1C and
Table S1).
Clinical characteristics of patients carrying JAK2 exon 12
mutations
The patients included three male and three female patients with
median age of 64 years (range 20–88). PV1, PV2 and PV4 had
enlarged spleens at the time of diagnosis verified on abdominal
ultrasound-scan (Table S1). Later on PV3 and PV6 developed
enlarged spleens during progression of disease. At the time of
diagnosis all patients had elevated hematocrit (median 0.6; range
0.56–0.81) and normal platelet counts and one patient had
persistent leukocytosis (PV4). Bone marrow (BM) biopsies were
hypercellular with characteristics consistent with MPN in 5
patients. BM evaluation was not performed in PV6. None had a
history of thrombosis at the time of diagnosis, but occurred at a
later time in PV2 (not shown). All patients were initially treated
with phlebotomy and aspirin in addition; both PV2 and PV4
needed supplementary cytoreductive therapy with hydroxyurea
due to thrombosis and leukocytosis, respectively (Table S1).
Quantitative determination of mutant JAK2 exon 12
allele burden
The correlation coefficients of standard curves were all above
0.990 and an average slope of 23.4 was determined from several
standard curve experiments (Figure 2A). The Y-intercept corre-
sponding to one target gene copy was determined for each primer
set by series of two-fold dilutions of both genomic DNA (gDNA)
and plasmids. The mutant copy number (JAK2mut) was then
determined by the equation 10‘(Y-intercept2CtJAK2mut/2slope-
JAK2mut) and the wildtype (wt) copy number (JAK2wt) by the
equation 10‘(Y-intercept2CtJAK2wt/2slopeJAK2wt). The percentage
mutant allele burden was then calculated as (Copy number
(JAK2mut)/[Copy number (JAK2mut)+Copy number (JAK2wt)])6100.
Cross-reaction with the wt sequence of the mutant specific assay
was determined by amplification of gDNA pooled from 42 healthy
donors. Unspecific amplification occasionally occurred for the
V536-I540dup11 primers but always with a difference in Ct values
of at least 18 Cts corresponding to a sensitivity of at least 1/
(1.93
18)=0.0007% (not shown). For significant detection of the
mutation a 10 fold higher cut-off was set to a maximal sensitivity
for the V536-I540dup11 mutation of 0.007%. The sensitivity of
the individual samples was calculated from the equation (1/[Copy
number (JAK2mut)+Copy number (JAK2wt)])6100. (Tables S2, S3,
S4, S5). Plasmids containing the mutated sequence were diluted
into wt gDNA and least 1.9 mutant copies could be detected in a
total of 15.000 JAK2 copies corresponding to 0.01% mutated
alleles (Figure 2B). The sensitivities for the samples were below
0.01% except for a few samples with limited amount of DNA
(Tables S2, S3, S4, S5).
To ensure that the assays demonstrated reproducibility suitable
for clinical applications eleven patient samples including high,
intermediate, and low mutant allele burdens were analysed from
six separate qPCR runs. The assays were highly reproducible with
no more than a 1.5 fold difference recorded within a dataset
(Figure 3 and Table S6).
Mutant allele burden in patient samples
The patients with K539L and the novel F537-I540delinsLV
mutations (PV4 and PV6, respectively) had a remarkably high
homozygous allele burden of 89% and 99% respectively
(Supplementary Tables S1 and S5). The heterozygous patients
PV1, PV3 and PV5 had low intermediate to intermediate levels of
Figure 1. Identification of JAK2 exon 12 mutations. A: Sequence of F537-I540delinsLV mutation of PV4 revealing a 10 base-pair deletion and a
four base-pair insertion. B: Difference plot of high resolution melting (HRM) analysis detecting N542-E543del, F537-I540delinsLV and K539L JAK2 exon
12 mutations in PV1, PV3, PV4, PV5 and PV6. C: Phase-contrast microphotograph showing Epo-independent growth of endogenous erythroid
colonies (EEC) at day 14 of culture. Scalebar: 200 mm. HRM, high resolution melting.
doi:10.1371/journal.pone.0033100.g001
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very low mutant allele burden ranging from of 1.5–3.4% (Tables
S1, S2, S3, S4, S5).
To investigate the development of the mutated clones,
variations in mutant allele burdens were investigated for PV1,
PV2, and PV3 for 420, 735, and 203 days, respectively. The
mutant allele burdens were stable over time for the intermediate
and low level mutant allele burdens investigated (Figure 4 and
Tables S2, S3, and S4).
Analysis of DNA extracted from paraffin embedded BM
samples resulted in sensitivities in the range of 0.007–0.016%
(Table S5). This was presumably the result of lower concentrations
of DNA and fragmentation following decalcifying acid treatment
of the samples. Consequently, no usable DNA could be obtained
from BM of patients PV5 and PV6. The mutant allele burden in
BM was slightly higher than in the PB in PV1 (40% in BM
compared to 24–33% in PB), but similar for PV3 (17% in BM
compared to 19–22% in PB) and PV4 (95% in BM compared to
99% in PB), whereas the mutant allele burden in PV2 was
significantly higher in the BM sample (21% in BM compared to
1.5% in PB) (Figure 5 and Table S5).
Cell sorting
The allele burden of the JAK2 exon 12 mutation was analysed
by qPCR for the granulocyte, monocyte, B-lymphocyte and T-
lymphocyte cell populations isolated by fluorescence activated cell
sorting (FACS) (Figure S1). Limitations in cell number in the
sorted fractions resulted in sensitivities up to 2.1% (Table S5).
However, all were below the sorting purities of the isolated cell
fractions, defining lower detection limits for CD16 positive
granulocytes and CD19 positive B-lymphocytes to 2% mutated
alleles, CD3 positive T-lymphocytes to 7% mutated alleles and
CD14 positive monocytes to 8% mutated alleles. The mutant
allele burden of the granulocyte fraction closely resembled that of
PB (Figure 5). The allele burden in the monocyte compartment
also resembled that seen in PB, except for PV2 where no mutation
could be detected, and PV5 where no mutation was detected as a
result of very low levels of DNA for this fraction (Table S3). JAK2
exon 12 mutations were detected in B-lymphocytes in half of the
patients with allele burdens above the detection limit, but not in T-
lymphocytes as the mutant allele burden of 6.6% in PV4 could
stem from sorting impurities (Figure 5).
Figure 2. Amplification plots of dilution series and standard curve of qPCR assay. A: Representative amplification plots of plasmid
containing JAK2 exon 12 mutation diluted into wildtype genomic DNA detected by the mutation specific assay. The ten fold dilution series starting at
15,000 copies is continued as two-fold dilutions after 15 copies down to 1.9 copies as indicated. B: Representative standard curve for the mutation
and wildtype assays producing correlation coefficients .0.990. The average slope of the standard curves was 23.4.
doi:10.1371/journal.pone.0033100.g002
Figure 3. Reproducibility of mutant allele burden determina-
tion by the qPCR assays. Histogram plots showing reproducibility of
percentage mutant allele burden in six separate qPCR runs. The mutant
allele burden was determined for 11 different DNA samples from four
different patients as indicated. The JAK2 exon 12 mutations include
K539L (PV6), V536-I546dup11 (PV4), and N542-E543del (PV1 and PV2) in
high, intermediate and low levels of mutant allele burden. The data is
presented as percentage mean values 6 standard deviation (SD).
doi:10.1371/journal.pone.0033100.g003
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In the present study, a highly sensitive qPCR assay was
developed for assessing the allele burden of the identified exon 12
mutations in PB and cell populations isolated from PB. The
method improves the current sensitivity for detection of exon 12
mutations and enables monitoring of the mutational status even
for very low mutant allele burdens.
Two different strategies were established to screen for JAK2
exon 12 mutations in patients with MPN: qPCR or HRM
combined with Sanger sequencing. Sanger sequencing is a reliable
technique when investigating a wide variety of mutations but has a
detection limit of 10–20% mutated alleles. Various HRM assays
have been developed with sensitivities depending on the assay and
mutation (1–20%) [26–28,30]. As it has been suggested that there
are no clinical differences among the JAK2 exon 12 mutation
variants [22], HRM analysis may at present be the best techniques
for investigation of routine samples, but is not sufficiently sensitive
as a pre-qPCR screen. A recent technique combining clamped
PCR with fragment analysis revealed the identity of the mutated
sequence and had a sensitivity of 0.1%, but this was only
investigated for the N542-E543del mutation [29]. The qPCR
assay of the present study is at least ten fold more sensitive. Using a
less sensitive technique to screen samples for JAK2 exon 12
mutations, would abrogate the superior sensitivity of the developed
qPCR technique in identifying patients with very low allele
burden. Accordingly, using qPCR we screened for eight of the
most common exon 12 mutations representing at least 62% of all
reported JAK2 exon 12 mutations [25] and 85% of JAK2 exon 12
mutations of a recent European multicenter study [22]. The
necessity for subsequent Sanger sequencing of the samples to
identify mutations not included in the initial screen was
highlighted by identification of the two patients carrying the
V536-I546dup11 and the F537-I540delinsLV mutations. To the
authors knowledge the F537-I540delinsLV mutation has not been
described previously.
It could be argued that using a HRM assay is more convenient
for large scale routine screening, but using only this technique the
N542-E543del mutation of PV2 in the present study would have
eluded detection. Furthermore determining the exact identity of a
mutation can be very challenging or impossible when using HRM
on samples with a mutant allele burden below the detection limit
of Sanger sequencing.
The risk of false positives is an important issue, especially when
using very sensitive techniques and confirmation of results
obtained by a technique with unrivalled sensitivity is inherently
difficult. The N542-E543del mutation of PV2 was the only
mutation detected by qPCR which could not reliably be confirmed
Figure 4. Time-course of JAK2 exon 12 allele burden development. A and B: Graphs describing the development of the N542-E543del mutant
allele burdens of PV1 and PV2 during a 420 and 735 day period respectively. C: Plot of V536-I546dup11 mutant allele burden of PV3 during a 203 day
period.
doi:10.1371/journal.pone.0033100.g004
Figure 5. Mutant JAK2 exon 12 allele burden in bone marrow and peripheral blood cell lineages. Histogram plot displaying the JAK2
exon 12 mutation burden in bone marrow, peripheral blood, CD16
+ granulocytes, CD14
+ monocytes, CD3
+ T-lymphocytes, and CD19
+ B-lymphocytes
in patients PV1-PV6. PV2 had very low level of JAK2 exon 12 mutant allele burden except for the bone marrow sample. PV1-PV3 and PV5 appeared to
be heterozygous, whereas PV4 and PV6 were homozygous. Note that DNA from bone marrow samples could not be obtained from patients PV5 and
PV6. BM, bone marrow and PB, peripheral blood.
doi:10.1371/journal.pone.0033100.g005
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separate DNA samples of PV2 were isolated over a period of 735
days and were positive for the mutation in a total of 37 triplicates
performed in 11 separate plates, run on different days. This
strongly suggests that PV2 is indeed a true positive.
The mutant allele ratios of PV1, PV2 and PV3 were stable over
time, resembling observations in JAK2V617F patients [31]. The
JAK2 exon 12 allele burden was comparable in PB and BM patient
samples, as has been reported earlier for patients carrying the
JAK2V617F mutation [32].
Interestingly, corresponding to the large discrepancy between
mutant allele burden in PB and BM of PV2, Larsen et al., also
reported significantly higher mutant allele burden in the BM of a
patient with a relatively low JAK2V617F mutant allele burden
[32]. In the context of using the mutant allele burden as a
prognostic factor further studies are needed to clarify if there are
patients with inconsistencies between mutant allele burden in the
PB and the BM.
The corresponding allele burdens for PB and for the
granulocyte fractions suggest that isolation of granulocytes does
not decrease the frequency of false negatives, even at very low
mutant allele burden, and is thus unnecessary. Instead, ‘‘whole
blood qPCR’’ is advocated, which has also been shown to be a
highly reliable methodology in assessing the JAK2V617F -allele
burden [23,32]. Exon 12 mutations were detected in B-
lymphocytes in half of the patients analysed, although not
conclusively in T-lymphocytes, which supports a previous report
that these mutations are present in the lymphoid compartment
[33]. The reduction of the qPCR sensitivity resulting from the
limited amount of cells in the sorted cell fractions was not of any
concern, as it did not rise above the sorting purity cut-off for the
positive samples. The low allele burden of the B-lymphocytes did
not correspond to the allele burden of PB suggesting that the exon
12 mutations do not impose a selective advantage on the
differentiation and/or expansion of the lymphoid compared to
the myeloid cells. Although leukocyte counts were in the normal
range for PV1 and PV5, it is interesting to note that PV4 - the
patient with the highest mutant allele burden in B-lymphocytes -
had an elevated leukocyte count. Evaluation of the JAK2 exon 12
mutant allele burden as a prognostic marker, however, requires
the investigation of a larger patient material.
Patients with JAK2 exon 12 mutations may proceed along a
clinical course very similar to those with the JAK2V617- mutation,
implying steadily progressive disease with development of MF
[22,34]. In the context that IFN-a-2 is able to induce major and
complete molecular remissions in JAK2V617F -positive patients it
is foreseen that similar results may be achieved in JAK2 exon 12
positive patients as well. In this setting the present report calls for
larger clinical studies evaluating the efficacy of IFN-a-2 in
inducing low-burden JAK2 exon 12 in this patient cohort and
the impact on disease evolution as well. In conclusion, the sensitive
and quantitative technique presented in the current study provides
a powerful tool for evaluating the mutant allele burden as a
prognostic factor and for monitoring of the mutant allele burden
during treatment with IFN-a-2.
Materials and Methods
Patients
The study included two cohorts. Cohort 1 consisted of 60
patients with MPN from Herlev hospital, including four patients
with idiopathic erythrocytosis (IE) and 56 patients classified
according to the World Health Organization (WHO) criteria
[1]: 15 ET, 37 PV and 4 primary MF (PMF). Cohort 2 included
102 patients from Rigshospitalet with suspected MPN submitted
for routine JAK2V617F analysis. All patients were tested negative
for the JAK2V617F mutation using a sensitive qPCR assay [23].
The procedures used were approved by the Capital Region
Committee on Health Research Ethics. The study was carried out
according to the declaration of Helsinki.
DNA analysis and Epo –independent Endogenous Colony
growth
DNA from PB was extracted using the Qiaamp DNA mini kit
(Qiagen, Hilden, Germany) according to manufacturer’s instruc-
tions. JAK2 exon 12 mutations in samples from cohort 1 were
identified by real-time qPCR screening for the exon 12 mutation
variants, in addition to Sanger sequencing as described below.
JAK2 exon 12 mutations in cohort 2 samples were identified by
HRM analysis followed by subsequent genotyping by sequencing.
Samples with a mutation identified either by real-time qPCR,
HRM and/or sequencing were investigated for Erythropoietin
(Epo) -independent Endogenous Colony (EEC) –growth from PB
using MethoCult Agar-LCM according to manufacturer’s instruc-
tions (Stemcell technologies, Grenoble, France).
qPCR design
The JAK2 exon 12 qPCR screening assays were designed for the
wt sequence and the mutations: N542-543del, E543-D544del,
K539L, F537-K539delinsL, H538-K539delinsL, H538QK539L,
R541-E543delinsK, and I540-E543delinsMK. After identification
of the mutations by Sanger sequencing (see results) quantitative
assays were also designed for the V536-I546dup11 and F537-
I540delinsLV mutations. The design included a common forward
primer and probe in addition to a wt or mutation specific primer,
resulting in a PCR product of approximately 130 bp. To increase
the sensitivity a mismatch was introduced at the 39end of the
reverse primers, except for H538-K539delinsL, V536-I546dup11,
N542-E543del, and F537-I540delinsLV. For quantitative analysis,
a common wt reverse primer was used, except the mutation N542-
E543del for which a specific reverse wt primer was designed
(Table 1). Standard curves were generated using plasmids
containing the exon 12 mutations flanked by 176 bp of the
upstream intron and 240 bp of the downstream intron (GeneArt,
Regensburg, Germany). The plasmids were transfected into
competent E. Coli (Invitrogen, Paisley, United Kingdom) and
extracted using Genelute TM HP Endotoxin free plasmid
maxiprep kit (Sigma-Aldrich, St. Louis, Missouri). The plasmid
sequence was confirmed by sequencing. The qPCR reaction was
performed in triplicate on 50 ng gDNA in a volume 25 ml
containing 300 ng/ml primers and 100 ng/ml probe. The two-step
PCR reaction were initiated by a heat activation step for 10 min at
95uC followed by 50 cycles of 15 s at 95uC and 60 s at 60uC. The
qPCR reactions were carried out using the Brilliant II qPCR
Master Mix on an MxPro3000 (Agilent, Santa Clara, California).
The relevant PCR product was subsequently sequenced for
confirmation. Plasmids containing the relevant mutated sequence
were used for positive control whereas a pool of gDNA of 42
healthy donors was used as a negative control and to determine
unspecific amplification of the wt sequence by the mutant specific
assays.
High resolution melting (HRM) design
A 164 amplicon was generated using M13-tagged primers in
JAK2 exon 12 (59-CCAACCTCACCAACATTACAGA-39) and
intron 12 (59- CCAATGTCACATGAATGTAAATCAA-39).
PCR-reactions were performed in a 15 ml volume and included
Mutant JAK2 Exon 12 Allele Burden Assessed by qPCR
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Technologies, Salt Lake City, Utah), 200 mM dNTPs, 0.2 mMo f
each primer, 0.025 U HotStarTaq DNA Polymerase (Qiagen) and
approximately 40 ng DNA. Amplification was achieved by
touchdown PCR performed on a GeneAmp 2700 (Applied
Biosystems, Foster City, California). Heteroduplexes were gener-
ated by raising the temperature of the PCR products to 95uC for
30 seconds and allowing the PCR products to slowly cool to room
temperature. Samples were subsequently transferred to the Light
Scanner instrument (Idaho Technologies) for HRM analysis. To
increase the ability to detect homozygous variants, sample mixing
was used to generate artificial heteroduplexes as described by
Vossen et al., [35]. After sample mixing the samples were again
analysed on the Light Scanner instrument.
Sanger sequencing of cohort 1 and cohort 2 samples
Cohort 1 samples were sequenced using the Big Dye
Terminator v1.1 Cycle Sequencing kit (Applied Biosystems) on
an ABI 3100 Genetic analyzer (Applied Biosystems).
Samples in cohort 2 where HRM analysis indicated possible
sequence variation were directly purified with Exo-SAP (Fermen-
tas, St. Leon-Rot, Germany) and then sequenced.
Extraction of DNA from paraffin-embedded tissues
DNA was extracted from 20 10 mm thick paraffin bone marrow
sections that where initially deparaffinised by xylene followed by
2696% EtOH. Tissues were digested by overnight treatment with
proteinase K in ATL buffer (Qiagen) and DNA was extracted
using the QiaAmp DNA mini kit (Qiagen) according to
manufacturer’s instructions.
Cell sorting
Red blood cells of PB were lysed using Ortho-Mune Lysis
Solution (Herlev Hospital pharmacy, Herlev, Denmark). For
isolation of granulocytes and T-lymphocytes, the cells were
labelled with monoclonal CD16-fluorescein isothiocyanate (FITC)
(DAKO, Glostrup, Denmark) and CD3- phycoerythrin (PE) (BD
Biosciences, San Jose, California). Prior to monocyte and B-
lymphocyte sorting, peripheral blood mononuclear cells (PBMC)s
were prepared using Leucosep according to manufacturer’s
instructions (Greiner bio-one, Frichenhausen, Germany) and then
labelled with monoclonal CD19-FITC and CD14-PE (BD
Biosciences). The cells were sorted on a FACSAria (BD
biosciences) in purity mode. Analysis of sorted cells revealed
purities of 98% for CD16 positive granulocytes, 93% for CD3
positive T-lymphocytes, 98% for the CD19 positive B-lympho-
cytes, and 92% for CD14 positive monocytes.
Supporting Information
Figure S1 Scatter plots of gating strategy for cell
sorting. Scatter plots for gating strategy employed for isolation
of A: CD16-FITC, B: CD3-PE, C: CD19-FITC, and D: CD14-PE
performed as double labelled sorting with gates for the isolation of
CD16
+ granulocytes and CD3
+ T-lymphocytes from peripheral
blood (blood) and in CD14
+ monocytes and CD19
+ B-lympho-
cytes isolated from peripheral blood mononuclear cells (PBMC).
Back gating for separation of labelled cells and single cell isolation
in forward- and side scatter plots is illustrated with colours
(CD16
+/CD3
+ singlets: blue/pink, CD19
+/CD14
+ singlets: blue/
pink. Cells were gated for cell type on FSC/SSC plot prior to
flourophore gating. Singlets were obtained by gating in FSC-H/
FSC-A and subsequently SSC-H/SSC-A. PBMC, peripheral
blood mononuclear cells.
(TIF)
Table S1 Clinical features of PV patients with JAK2
exon 12 mutations. Clinical data at time of diagnosis as
indicated. Cell counts are in610
9/L. F, female; M, Male; Diagn.,
diagnosis; PV, polycythemia vera; Years, years from diagnosis;
%mut, JAK2 exon 12 mutant allele burden at time of cell sorting;
Table 1. Primer and probe sequences for JAK2 exon 12.
Primers Sequence 59-39
JAK2exon12-Forw CAGATAAATCAAACCTTCTAGTCTTC
JAK2exon12-wt-Rev CAAATCTTCATTTCTGATTTTGTtA
JAK2exon12-N542-E543del-Rev TGACTTACAAATATCAAATCTCTGA
JAK2exon12-E543-D544del-Rev CAAATCTTCATTTCTGATTAAGTtA
JAK2exon12-K539L-Rev CAAATCTTCATTTCTGATTAAGTtA
JAK2exon12-H538-K539delinsL-Rev AAATATCAAATCTTCATTTCTGATTAAA
JAK2exon12-I540-E543delinsMK-Rev CAAATATCAAATCTTTCATTTTGTtA
JAK2exon12-H538QK539L-Rev CAAATCTTCATTTCTGATTAATTtA
JAK2exon12-R541-E543delinsK-Rev CAAATATCAAATCTTTGATTTTGTtA
JAK2exon12-F537-K539delinsL-Rev CAAATCTTCATTTCTGATTAACACtA
Primers only for quantitative determination
JAK2exon12-wt (N542-E543del)-Rev AATGACTTACAAATATCAAATCTTCA
JAK2exon12-V536-I546dup11-Rev TTTGTGAAACACTATCAAATCTTC
JAK2exon12-F537-I540delinsLV-Rev AAATATCAAATCTTCATTTCTCACTA
Probe
JAK2exon12 probe Fam-CCAACCTCACCAACATTACAGAGGCC-Tamra
Primers used for qPCR screening and quantitative determination consisting of a common forward primer and probe in addition to a mutation specific reverse primer.
The primers listed for quantitative determination were only used exclusively for determination of mutant allele burden. Lowercase letters in sequences indicate
intended mismatches.
doi:10.1371/journal.pone.0033100.t001
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Trc, platelet count; Epo, erythropoietin; Norm., normal; Spleen,
spenomegaly; Thromb, previous thromboses; BM, bone marrow;
EEC, Epo-independent Endogenous Colony -growth; Seq,
sequencing; Treat, treatment; Hu, hydroxyurea; V, venesection;
A, Aspirin.
* PV3 and PV6 later developed splenomegaly and PV6 had an
incidence of transient cerebral ischemic attack.
(PPT)
Table S2 Development of N542-E543del mutant allele
burden in PV1. Data for PV1 displaying the percentage mutant
allele burden of JAK2 exon 12 mutations during a time period of
420 days, depicted in Figure 3. Mut (%), percentage mutant allele
burden and Sens (%), percentage sensitivity.
(XLS)
Table S3 Development of N542-E543del mutant allele
burden in PV2. Data for PV2 displaying the percentage mutant
allele burden of the JAK2 exon 12 mutation during a time period
of 735 days, depicted in Figure 4. Mut (%), percentage mutant
allele burden and Sens (%), percentage sensitivity.
(XLS)
Table S4 Development of V536-I546dup11 mutant allele
burden in PV3. Data for PV3 displaying the percentage mutant
allele burden of JAK2 exon 12 mutations during a time period of
203 days, depicted in Figure 4. Mut (%), percentage mutant allele
burden and Sens (%), percentage sensitivity.
(XLS)
Table S5 qPCR data of bone marrow, peripheral blood
and sorted cell fractions. Data for patients PV1-PV6
presented in histogram plots shown in Figure 5. showing
percentage mutated JAK2 exon 12 alleles of BM, PB, and sorted
cell fractions (CD16
+ granulocytes, CD14
+ monocytes, CD3
+ T-
lymphocytes, and CD19
+ B-lymphocytes). Furthermore the
sensitivities are shown calculated as described. BM, bone marrow;
PB, peripheral blood; neg., negative; n/a, not available.
(XLS)
Table S6 Reproducibility analysis of qPCR assay. Values
from reproducibility assay histogram plots presented in Figure 3.
The column row indicates the histogram columns of Figure 3. The
identity of the mutations for the individual patients in addition to
coefficient of variation and mean values 6 standard deviations
(SD) are shown.
(XLS)
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